Agreed Zolrab - and these royalties going to WARF are a percentage of OUR royalty, not a percentage of the total royalty.
This represents a very nice deal to me; but in todays announcement I particularly like -
"The endorsement by Fujifilm of Cynata’s Cymerus platform supports the continued commercialisation of Cynata’s cell therapeutic products in other indications, including CYP002 for critical limb ischemia (CLI) and CYP-004 for osteoarthritis."
A clear statement outlining the next two commercial products ready to be rolled out. My own prediction fwiw would be Sumitomo readjusting their bid to 3-4 dollars in light of today's exciting developments.
Ann: Fujifilm Exercises License Option in GvHD, page-123
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.21M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $8.574K | 36.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 20475 | 2 |
View Market Depth
| Last trade - 15.43pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.000 ( 2.08 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.5¢ | 22.5¢ | 22626 | ||
| Last updated 13.57pm 07/05/2024 ? | |||||
| CYP (ASX) Chart |